Celldex Therapeutics (CLDX) News
NASDAQ: CLDXHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
27.42-0.54 (-1.93%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CLDX news summary
We found 5 recent headlines mentioning Celldex Therapeutics (CLDX): 2 in the past week and 3 in the past 30 days, most often from Nasdaq, GlobeNewswire, PR Newswire. For price context, CLDX is down 1.93% at $27.42. The most recent story, "Celldex Ends Barzolvolimab Development In Atopic Dermatitis After Phase 2 Trial Misses Key Endpoints", was published by Nasdaq on Nov 20, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Celldex Therapeutics headlines
- Celldex Ends Barzolvolimab Development In Atopic Dermatitis After Phase 2 Trial Misses Key Endpoints(RTTNews) - Celldex Therapeutics, Inc. (CLDX) on Thursday stated it is discontinuing development of barzolvolimab in atopic dermatitis (AD) after the Phase 2 trial missed its primary and secondary…Nasdaq
- Celldex Reports Results from Phase 2 Study of Barzolvolimab in Atopic DermatitisHAMPTON, N.J., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported topline results from the Company’s Phase 2 study of barzolvolimab in moderate to severe atopic dermatitis (AD).…GlobeNewswire
- Celldex Therapeutics Reports Third Quarter 2026 Financial ResultsCelldex Therapeutics, Inc. reported its financial results for the third quarter ended September 30, 2026. The company recorded a net loss of $75.6 million, or ($0.96) per share, for the third quarter…Nasdaq
- SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Celldex Therapeutics, Inc. (NASDAQ: CLDX) on behalf of the company's shareholders. The investigation…PR Newswire
- Weekly Buzz: MESO, LLY, ANIP Win FDA Nod; KALA, HCTI Sign LOI; IMVT Halts Lupus Study(RTTNews) - Biotech and pharma companies delivered a busy slate of updates, spanning regulatory approvals, multibillion-dollar drug discovery partnerships and pivotal clinical-trial readouts across…NasdaqABBV, ABEO, AMRX, ANIP